CytoDyn Secures $30 Million Commitment from Yorkville Advisors
November 3, 2025
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
September 8, 2022
Related Post
-
-
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy
November 3, 2025
-
Biofrontera Inc.: A Compelling Investment in Dermatology
October 28, 2025
-
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
October 23, 2025